R&D Costs and Productivity in Biopharmaceuticals

DSpace/Manakin Repository

R&D Costs and Productivity in Biopharmaceuticals

Citable link to this page


Title: R&D Costs and Productivity in Biopharmaceuticals
Author: Scherer, Frederic Michael
Citation: Scherer, F.M. 2011. R&D Costs and Productivity in Biopharmaceuticals. HKS Faculty Research Working Paper Series RWP11-046, John F. Kennedy School of Government, Harvard University
Full Text & Related Files:
Abstract: This article characterizes the activities required to launch a new pharmaceutical molecule into the market, summarizes studies that have attempted to pinpoint the research and development costs incurred per approved new molecule, and analyzes the various critiques levied against published R&D cost estimates. It finds that by any reckoning, R&D costs per approved molecule have risen sharply over time, most likely at a rate of approximately 7 percent per year after stripping out the effects of general economic inflation.
Published Version: http://web.hks.harvard.edu/publications/workingpapers/citation.aspx?PubId=8094
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:5688848
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search